We are live on ! Find out more
ENZN

ENZON PHARMACEUTICALS INC
ENZN

Delisted

ENZN was delisted on the 19th of May, 2016.

75 hedge funds and large institutions have $27.9M invested in ENZON PHARMACEUTICALS INC in 2014 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 21 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 21

5% less funds holding

Funds holding: 7975 (-4)

18% less capital invested

Capital invested by funds: $34.2M → $27.9M (-$6.32M)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

85% less call options, than puts

Call options by funds: $3K | Put options by funds: $20K

Holders
75
Holders Change
-4
Holders Change %
-5.06%
% of All Funds
2.17%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
22
Reduced
21
Closed
10
Calls
$3K
Puts
$20K
Net Calls
-$17K
Net Calls Change
-$19K
Name Holding Trade Value Shares
Change
Change in
Stake
IC
1
Icahn Carl
Florida
$6.08M
BIT
2
BlackRock Institutional Trust
California
$3.57M +$366K +354,236 +11%
State Street
3
State Street
Massachusetts
$1.46M +$115K +111,479 +9%
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.33M +$22.9K +22,188 +2%
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
$1.25M -$18.4K -17,813 -1%
BFA
6
BlackRock Fund Advisors
California
$1.1M +$10.4K +10,083 +1%
BIP
7
Brandes Investment Partners
California
$1.08M +$25.3K +24,530 +2%
Renaissance Technologies
8
Renaissance Technologies
New York
$1M +$213K +206,700 +27%
BA
9
BlackRock Advisors
Delaware
$866K +$52.5K +50,827 +6%
Fidelity Investments
10
Fidelity Investments
Massachusetts
$821K -$121K -117,054 -13%
MFP
11
Michael F. Price
$771K
U
12
UBS
Switzerland
$724K -$5.97K -5,779 -0.8%
Citadel Advisors
13
Citadel Advisors
Florida
$579K +$450K +435,573 +342%
Northern Trust
14
Northern Trust
Illinois
$507K -$49.9K -48,365 -9%
Goldman Sachs
15
Goldman Sachs
New York
$459K -$55.8K -54,063 -11%
Morgan Stanley
16
Morgan Stanley
New York
$432K +$84K +81,336 +24%
California Public Employees Retirement System
17
California Public Employees Retirement System
California
$359K +$348K +337,000 +521%
FPA
18
First Pacific Advisors
California
$357K
PAMU
19
Pictet Asset Management (UK)
United Kingdom
$326K
SO
20
STRS Ohio
Ohio
$311K
MERSOM
21
Municipal Employees' Retirement System of Michigan
Michigan
$309K +$309K +299,600 New
Invesco
22
Invesco
Georgia
$292K +$192K +185,557 +189%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$278K +$64K +61,955 +30%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$268K -$11.8K -11,418 -4%
Connor, Clark & Lunn Investment Management (CC&L)
25
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$257K +$35.8K +34,700 +18%

ENZN Hedge Fund Activity: Q1 2014 in Review

75 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in ENZON PHARMACEUTICALS INC (ENZN) for Q1 2014, worth a combined $27.9M — down 18% from $34.2M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of ENZN and 7 opened new positions — a net loss of 3 holders — while 21 trimmed existing stakes and 22 added.

The largest buyer was Citadel Advisors, adding an estimated $450K. The largest seller was Baupost Group, exiting entirely with an estimated $5.03M sold.

  • 75 institutional investors held ENZON PHARMACEUTICALS INC (ENZN) as of Q1 2014, down from 79 in Q4 2013.
  • Funds reported $27.9M of ENZON PHARMACEUTICALS INC stock for Q1 2014, down 18% quarter-over-quarter.
  • 7 funds opened new ENZON PHARMACEUTICALS INC positions in Q1 2014 and 10 closed out, a net change of -3 holders.
  • The largest ENZON PHARMACEUTICALS INC buyer in Q1 2014 was Citadel Advisors, an estimated $450K added.
  • The largest ENZON PHARMACEUTICALS INC seller in Q1 2014 was Baupost Group, an estimated $5.03M sold.

Based on aggregated 13F filings for Q1 2014.